Table 1.
Demographic and clinical data.
| Parameter | Leak (n = 30) | No leak (n = 408) | P value |
|---|---|---|---|
| Gender (M (%)) | 23 (76.7) | 222 (54.4) | 0.018 |
| Age (≥60 y, n (%)) | 24 (80.0) | 273 (66.9) | 0.139 |
| Diabetes (n (%)) | 9 (30.0) | 24 (5.88) | 0.001 |
| Cardiovascular disease (n (%)) | 8 (26.7) | 84 (20.6) | 0.430 |
| BMI (≥25 kg/m2, n (%)) | 20 (66.6) | 255 (62.5) | 0.648 |
| ASA score (3~4, n (%)) | 8 (26.7) | 132 (32.4) | 0.519 |
| Hb (≤110 g/L, n (%)) | 5 (16.6) | 60 (14.7) | 0.770 |
| ALB (≤35 g/L, n (%)) | 6 (20.0) | 30 (7.35) | 0.015 |
| Surgical method (laparoscopy, n (%)) | 28 (93.3) | 387 (94.9) | 0.719 |
| Prophylactic ileostomy (n (%)) | 9 (30.0) | 118 (28.9) | 0.900 |
| Tumor distance from anal verge (≤5 cm, n (%)) | 13 (43.3) | 96 (23.5) | 0.015 |
| Neoadjuvant CRT (n (%)) | 11 (36.6) | 42 (10.3) | 0.001 |
| TNM stage (III~IV, n (%)) | 16 (53.3) | 186 (45.9) | 0.411 |
| Tumor diameter (≥3 cm, n (%)) | 25 (83.3) | 270 (66.2) | 0.053 |
| Postoperative hospital stay (days, x ± s) | 24.5 ± 5.5 | 11.2 ± 4.1 | 0.001 |
Note: M: male; BMI: body mass index; ASA: American Society of Anesthesiologists; Hb: hemoglobin; ALB: albumin; CRT: chemoradiotherapy; TNM: tumor node metastasis.